Larimar Therapeutics, Inc. (LRMR) Stock Price & Analysis
Larimar Therapeutics, Inc. (LRMR) is trading at USD 3.23, up 7.86% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.
LRMR last closed at USD 3.23; today's session has ranged USD 2.93–3.35 on volume of 1,190,164 shares. Market capitalization is —, with a 52-week range of USD 1.92–6.42 (NGM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.
What changed for LRMR since Aug 31, 2025
The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).
- Larimar Therapeutics, Inc. (LRMR) stock went from USD 3.62 (close of the week of Aug 25, 2025, split-adjusted) to USD 3.22, a -10.9% price change; the S&P 500 (SPY) moved +14.9% over the same period.
- Analyst actions on LRMR in the last 120 days: 1 (0 upgrades or target raises, 1 downgrades or target cuts); most recent Wedbush, Aug 5, 2026.
Also available as compact Markdown for AI agents: nexqual.com/LRMR.md
Key facts (LRMR)
- Total return with dividends: 1Y -4.9% vs S&P 500 +11.9%; 5Y -68.5% vs S&P 500 +66.7%.
- Latest earnings report: 2026-11-16 (next date not yet announced).
- Dividend: LRMR paid no cash dividend in the last five years.
- Short interest: 15.50% of float (as of 2026-10-30), 7.1 days to cover.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LRMR)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172M | -$162M |
| Net income | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$166M | -$156M |
| EPS (diluted) | -$2.95 | -$1.37 | -$0.84 | -$1.32 | — | — |
| Free cash flow | -$42.4M | -$27.7M | -$33.6M | -$71.3M | -$113M | — |
| Cash + short-term investments | — | $118M | $86.8M | $184M | $137M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Sep 30, 2026) (LRMR)
P/B 3.3x · Earnings yield -46.53%
Analysts (LRMR)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-05 | Wedbush | Target lowered | Outperform | $12 → $11 |
Total return (dividends reinvested) (LRMR)
| 1Y (from 2025-11-18) | 5Y (from 2021-11-15) | |
|---|---|---|
| Total return | -4.9% | -68.5% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | -4.9% | -20.6% |
| Volatility (annualized) | 93.5% | 95.2% |
| Max drawdown | -66.6% (Feb 2026→Oct 2026) | -86.1% (Dec 2021→Aug 2022) |
Dividends (LRMR)
LRMR paid no cash dividend in the last five years.
Short interest (LRMR)
10,538,346 shares sold short, 15.50% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 15,369,771 shares (-31.4%). Days to cover: 7.1 (short shares ÷ average daily volume).
LRMR earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Nov 16, 2026 | Quarter ended Sep 30, 2026 | −$0.29 | −$0.36 | Beat +19.4% | -1.0% |
| Nov 9, 2026 | Quarter ended Sep 30, 2026 | −$0.29 | −$0.36 | Beat +19.4% | +12.6% |
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$0.30 | −$0.38 | Beat +21.1% | +3.0% |
| May 14, 2026 | Quarter ended Mar 31, 2026 | −$0.31 | −$0.59 | Beat +47.5% | -12.7% |
| Mar 19, 2026 | Quarter ended Dec 31, 2025 | −$0.73 | −$0.55 | Miss −32.7% | +4.4% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | −$0.73 | −$0.55 | Miss −32.7% | +0.0% |
| Nov 5, 2025 | — | — | — | — | -8.7% |
| Aug 14, 2025 | — | — | — | — | +7.8% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
LRMR recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Nov 16, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Nov 16, 2026 | Schedule 13G | RTW Investments, LP, Roderick Wong: 5.6% of shares, passive 5%+ holder |
| Nov 16, 2026 | 8-K | Quarterly results |
| Nov 9, 2026 | 8-K | Quarterly results; Other material event “Press Release On November 9, 2026, the Company issued a press release announcing that the Company completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Corporate Presentation On November 9, 2026, the Company posted on its website an…” |
| Sep 29, 2026 | 8-K | Director or executive officer change, or pay arrangement “The Board of Directors (the "Board") of Larimar Therapeutics, Inc. (the "Company") appointed John B. Harlow, Jr. as the Company's President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the "Employment Agreement"), effective as of September 29, 2026 (the "Effective Date"). Prior to joining the Company, Mr. Harlow, age 51, served as the Chief Commercial Officer at Esperion Therapeutics, Inc. (formerly Nasdaq: ESPR), a commercial stage biopharmaceutical company focused…” |
| Aug 4, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results; Other material event “On August 4, 2026, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LRMR suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | KBI Biopharma | “The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by KBI Biopharma, Inc. ("KBI").” |
| Supplier | Lonza | “Additional comparability of the drug substance manufactured by Lonza will need to be performed and reviewed by the FDA and other regulatory authorities in order to use the Lonza-manufactured drug substance in clinical and commercial activities.” |
Quoted from the company's 10-K filed Mar 19, 2026.
Companies that name LRMR in their SEC reports
| Relationship to LRMR | Company | Filing | Sentence |
|---|---|---|---|
| partner | Lexeo Therapeutics, Inc. (LXEO) | 10-K Mar 30, 2026 | “With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…” |
LRMR company outlook (results filed Nov 16, 2026)
- “The Company projects its cash runway into late Q2 2027.”
Quoted word-for-word from the SEC 8-K results press release.
LRMR analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $-0.33 | $-0.38 | +$0.05 | $0 | 6 |
| Next quarter (ends Mar 2027) | $-0.36 | $-0.39 | +$0.03 | $0 | 4 |
| Current fiscal year (ends Dec 2026) | $-1.18 | $-1.35 | +$0.17 | $0 | 4 |
| Next fiscal year (ends Dec 2027) | $-0.91 | $-1.06 | +$0.15 | $38.8M | 8 |
LRMR options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 2 | 262.1% | ±38.1% |
| Dec 18, 2026 | 30 | 171.6% | ±34.8% |
| Jan 15, 2027 | 58 | 90.0% | ±43.9% |
| Feb 19, 2027 | 93 | 94.5% | ±42.1% |
30-day implied volatility 86.4% vs 113.9% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of November 18, 2026 at 20:43 UTC)
| Price | USD 3.23 |
|---|---|
| Change | ▲ 7.86% (up) |
| Previous Close | USD 3.23 |
| Open | USD 3.23 |
| Day Range | USD 2.93 – 3.35 |
| 52-Week Range | USD 1.92 – 6.42 |
| Volume | 1,190,164 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (LRMR)
Nexqual's technical model rates LRMR "BUY" based on 5 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.99 (neutral) |
| vs SMA50 | Above (USD 2.88) |
| MACD | 0.08 (positive) |
Earnings (LRMR)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD -0.29 vs est -0.36 ▲ beat |
| 2026-06-30 | USD -0.3 vs est -0.38 ▲ beat |
| 2026-03-31 | USD -0.31 vs est -0.6 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -0.55 ▼ miss |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financials & Fundamentals (LRMR)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -129.75% |
| Debt / Equity | 0.05 |
| Current Ratio | 3.82 |
| Total Cash | $128.66M |
| Total Debt | $4.78M |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
Financial Health Score (LRMR)
Nexqual rates Larimar Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $129M cash vs $5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$113M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -154%, ROA -111.0% (last 4 quarters, SEC) |
Ownership (LRMR)
| Insider Ownership | +1.26% |
|---|---|
| Institutional Ownership | +101.09% |
| Shares Outstanding | 104.63M |
| Float | 57.15M |
| Short % of Float | +15.50% |
Source: Nexqual, November 18, 2026 at 20:43 UTC.
From Larimar Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
- In June 2025, the FDA provided recommendations regarding the safety data set that might be needed to support a Biologics License Application ("BLA") seeking accelerated approval, which included evaluating safety in at least 30 participants with continuous study drug exposure for six months and a subset of at least 10 of those participants with continuous study drug exposure for one year, with the large majority of data coming from participants receiving the 50 mg dose.
- As a result, we consulted experts and decided to modify the starting dose regimen and the FDA agreed with our approach.
- Using our proprietary peptide delivery technology, nomlabofusp is designed to carry the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off by the mitochondrial processing peptidase ("MPP") enzyme to yield mature FXN.
Partnerships
- We are party to a Master Services Agreement with Lonza, pursuant to which Lonza provides manufacturing services with respect to nomlabofusp.
- We may build our own internal sales force, partner with a contract sales organization, enter into a joint marketing partnership with another pharmaceutical or biotechnology company, or we may seek to out-license nomlabofusp.
Legal & Regulatory Risks (Item 1A, quoted)
- We may not be successful in our efforts to identify, discover or acquire additional product candidates.
- We may experience difficulties identifying and enrolling patients in our clinical trials given the number of ongoing trials being conducted and the limited number of patients who have the disease for which nomlabofusp is being studied or for any other product candidate we may study in the future.
- The conditions for which we are planning to evaluate nomlabofusp and any product candidates we may evaluate in the future, are rare genetic diseases.
- Our approach to discover and develop fusion proteins for delivering proteins is novel and may never lead to marketable products.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KOD | Kodiak Sciences Inc | USD 98.14 | ▲ 1.38% |
| BLTE | Belite Bio, Inc | USD 157.14 | ▼ 0.37% |
| IBRX | ImmunityBio, Inc. | USD 6.71 | ▲ 7.19% |
| ORKA | Oruka Therapeutics, Inc. | USD 95.92 | ▼ 0.42% |
| IMVT | Immunovant, Inc. | USD 33.3 | ▲ 0.27% |
| CGON | CG Oncology, Inc. | USD 79.9 | ▲ 1.22% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt